Hypermethylation of Apoptotic Genes in Oral Squamous Cell Carcinoma

Aabhas Agarwal

Department of Biotechnology, Sharda School of Engineering and Technology, Sharda University, Greater Noida-201310, India.

Shivani Tyagi

Department of Biotechnology, Sharda School of Engineering and Technology, Sharda University, Greater Noida-201310, India.

Madhav Kumar

Department of Biotechnology, Sharda School of Engineering and Technology, Sharda University, Greater Noida-201310, India.

Abhimanyu Kumar Jha *

Department of Biotechnology, Sharda School of Engineering and Technology, Sharda University, Greater Noida-201310, India.

*Author to whom correspondence should be addressed.


Abstract

Oral squamous cell carcinoma (OSCC) presents a substantial worldwide health challenge due to its aggressive behavior and resistance to standard treatments, resulting in high mortality rates. Epigenetic changes, notably DNA hypermethylation, are pivotal in OSCC development as they silence tumor-suppressor genes and drive tumor growth. This review highlights the hypermethylation status of apoptotic genes in the promoter region of CpG island which results in the formation of OSCC. This article utilizes different scientific databases such as Google Scholar, PubMed, NCBI, etc. to understand the interplay between external factors and epigenetic modifications which provides valuable insights for preventive strategies and personalized approaches to OSCC.  The review discusses the epidemiology and causes of OSCC, emphasizing its resistance to therapy and poor prognosis. It also assesses current treatment strategies targeting DNA hypermethylation, such as inhibitors of demethylation and histone deacetylase, for their potential to improve patient outcomes. Future research directions center on investigating combination therapies targeting various epigenetic regulators and creating non-invasive methods for early cancer detection and prognosis evaluation. Overall, this review underscores the significance of DNA hypermethylation in OSCC progression and highlights the therapeutic promise of addressing epigenetic changes, especially those affecting apoptotic genes, to enhance patient survival.

Keywords: Hypermethylation, apoptotic genes, cancer, epigenetics


How to Cite

Agarwal, A., Tyagi , S., Kumar , M., & Jha , A. K. (2024). Hypermethylation of Apoptotic Genes in Oral Squamous Cell Carcinoma. Asian Journal of Biotechnology and Genetic Engineering, 7(1), 96–111. Retrieved from https://journalajbge.com/index.php/AJBGE/article/view/128

Downloads

Download data is not yet available.

References

Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, Zheng Q. Natural products as anticancer agents: Current status and future perspectives. Molecules. 2022 Nov 30;27(23):8367.

D’souza S, Addepalli V. Preventive measures in oral cancer: An overview. Biomedicine & Pharmacotherapy. 2018 Nov 1;107:72-80.

Ferris RL, Blumenschein Jr G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2016 Nov 10;375(19):1856-67.

Jha M, Aggarwal R, Jha AK, Shrivastava A. Natural compounds: DNA methyltransferase inhibitors in oral squamous cell carcinoma. Applied biochemistry and biotechnology. 2015 Oct;177:577-94.

Kumar M, Jha AK. Exploring the potential of dietary factors and plant extracts as chemopreventive agents in oral squamous cell carcinoma treatment. Frontiers in Oral Health. 2023;4.

Kumar A, Sarode SC, Sarode GS, Majumdar B, Patil S, Sharma NK. Beyond gene dictation in oral squamous cell carcinoma progression and its therapeutic implications. Translational Research in Oral Oncology. 2017 Apr 6;2: 2057178X17701463.

Goel H, Singhal S, Mathur R, Syeda S, Gupta RK, Kumar A, Shrivastava A, Jha AK. Promoter hypermethylation of LATS2 gene in oral squamous cell carcinoma (OSCC) among North Indian population. Asian Pacific Journal of Cancer Prevention: APJCP. 2020;21(5):1283.

Andrews JL, Kim AC, Hens JR. The role and function of cadherins in the mammary gland. Breast cancer research. 2012 Feb;14:1-0.

Goel H, Mathur R, Syeda S, Shrivastava A, Jha AK. Promoter hypermethylation of LATS1 gene in oral squamous cell carcinoma (OSCC) among North Indian population. Asian Pacific Journal of Cancer Prevention: APJCP. 2021;22(3):977.

Feinberg AP, Tycko B. The history of cancer epigenetics. Nature Reviews Cancer. 2004;4(2):143-153.

Board RE, Knight L, Greystoke A, Blackhall FH, Hughes A, Dive C, Ranson M. DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomarker Insights. 2007 Jan;2: 117727190700200003.

Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003 Apr 18;300(5618):455-.

Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature reviews genetics. 2002 Jun 1;3(6):415-28.

Teodoridis JM, Strathdee G, Brown R. Epigenetic silencing mediated by CpG island methylation: Potential as a therapeutic target and as a biomarker. Drug Resistance Updates. 2004 Aug 1;7(4-5):267-78.

Hanahan D, Weinberg RA. The hallmarks of cancer. cell. 2000 Jan 7;100(1):57-70.

Bird A. DNA methylation patterns and epigenetic memory. Genes & development. 2002 Jan 1;16(1):6-21.

Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature reviews genetics. 2002 Jun 1;3(6):415-28.

Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William Jr WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer prevention research. 2015 Nov 1;8(11):1027-35.

Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics. 2009 May 16;4(4):255-64.

Völkel P, Angrand PO. The control of histone lysine methylation in epigenetic regulation. Biochimie. 2007 Jan 1;89(1):1-20.

Tedesco I, Russo M, Bilotto S, Spagnuolo C, Scognamiglio A, Palumbo R, Nappo A, Iacomino G, Moio L, Russo GL. Dealcoholated red wine induces autophagic and apoptotic cell death in an osteosarcoma cell line. Food and Chemical Toxicology. 2013 Oct 1;60:377-84.

Elmore S. Apoptosis: A review of programmed cell death. Toxicologic pathology. 2007 Jun;35(4):495-516.

Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. cell. 2011 Mar 4;144(5):646-74.

Green DR, Llambi F. Cell death signaling. Cold Spring Harbor perspectives in biology. 2015 Dec 1;7(12):a006080.

Ashkenazi A, Salvesen G. Regulated cell death: Signaling and mechanisms. Annual Review of Cell and Developmental Biology. 2014 Oct 6;30:337-56.

Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science. 1998;281(5381):1305-1308.

Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor Perspect Biol. 2009;1:a003129.

He S, Chakraborty R, Ranganathan S. Proliferation and apoptosis pathways and factors in oral squamous cell carcinoma. International Journal of Molecular sciences. 2022 Jan 29;23(3):1562.

Andrews JL, Kim AC, Hens JR. The role and function of cadherins in the mammary gland. Breast Cancer Research. 2012 Feb;14:1-0.

Kadeh H, Parsamanesh N, Miri‐Moghaddam E. Effect of CDH1 and CDH2 genes polymorphisms in oral squamous cell carcinoma susceptibility in a sample of Iranian population: A case‐control study. Health Science Reports. 2023 Apr;6(4):e1221.

Supic G, Kozomara R, Jovic N, Zeljic K, Magic Z. Prognostic significance of tumor-related genes hypermethylation detected in cancer-free surgical margins of oral squamous cell carcinomas. Oral oncology. 2011 Aug 1;47(8):702-8.

Chang HW, Chow V, Lam KY, Wei WI, Wing Yuen AP. Loss of E‐cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer. 2002 Jan 15;94(2):386-92.

Kordi-Tamandani DM, Moazeni-Roodi AK, Rigi-Ladiz MA, Hashemi M, Birjandian E, Torkamanzehi A. Promoter hypermethylation and expression profile of MGMT and CDH1 genes in oral cavity cancer. Archives of Oral Biology. 2010 Oct 1;55(10):809-14.

Li C, Lu J, Liu Z, Wang LE, Zhao H, El-Naggar AK, Sturgis EM, Wei Q. The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck. Cancer Prevention Research. 2010 Feb 1;3(2):246-53.

Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000 Mar 1;21(3):485-95.

Andersen MH, Becker JC, Straten PT. Regulators of apoptosis: Suitable targets for immune therapy of cancer. Nature Reviews Drug Discovery. 2005 May 1;4(5):399-409.

Stupack DG. Caspase-8 as a therapeutic target in cancer. Cancer letters. 2013 May 28;332(2):133-40.

Khan Z, Khan AA, Yadav H, Prasad GB, Bisen PS. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cellular & Molecular Biology Letters. 2017 Dec;22:1-32.

Wheatley SP. The functional repertoire of survivin's tails. Cell Cycle. 2015 Jan 17;14(2):261-8.

Khan Z, Khan AA, Yadav H, Prasad GB, Bisen PS. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cellular & Molecular Biology Letters. 2017 Dec;22:1-32.

Altieri DC. Validating survivin as a cancer therapeutic target. Nature Reviews Cancer. 2003 Jan;3(1):46-54.

Kulkarni V, Saranath D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncology. 2004 Feb 1;40(2):145-53.

Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M, Shibata T. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. Journal of Cancer Research and Clinical Oncology. 2006 Nov;132:735-43.

Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. The Lancet Oncology. 2006 Jan 1;7(1):77-82.

Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. oncogene. 2002 Jun;21(27):4231-6.

Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Research. 2000 Feb 15;60(4):892-5.

Rosas SL, Koch W, Carvalho MD, Wu L, Califano J, Westra W, Jen J, Sidransky D. Promoter hypermethylation patterns of p16, O 6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Research. 2001 Feb 2;61(3):939-42.

Pal N, Rathore S, Kaushik P, Tyagi S, Jha AK, Kumar A. Promoter hypermethylation of apoptotic genes in oral squamous cell carcinoma. Cancer Therapy & Oncology International Journal. 2019;13(5):103-8.

Ragos V, Mastronikolis NS, Tsiambas E, Baliou E, Mastronikolis SN, Tsoukalas N, Patsouri EE, Fotiades PP. p53 mutations in oral cavity carcinoma. J. BUON. 2018 Nov 1;23(6):1569-72.

Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harbor Perspectives in Biology. 2010 Jan 1;2(1):a001008.

Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E. Key tumor suppressor genes inactivated by “greater promoter” methylation and somatic mutations in head and neck cancer. Epigenetics. 2014 Jul 15;9(7): 1031-46.

De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Molecular and cellular biology; 2004 Jun 1.

Huang KH, Huang SF, Chen IH, Liao CT, Wang HM, Hsieh LL. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clinical Cancer Research. 2009 Jun 15;15(12): 4174-80.

Taioli E, Ragin C, Wang XH, Chen J, Langevin SM, Brown AR, Gollin SM, Garte S, Sobol RW. Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation. BMC Cancer. 2009 Dec;9:1-1.

Kouzarides T. Chromatin modifications and their function. Cell. 2007 Feb 23;128(4):693-705.

Thangarajah F, Vogel C, Pahmeyer C, Eichler C, Holtschmidt J, Ratiu D, Mallmann P, Malter W. Profile and outcome of supraclavicular metastases in patients with metastatic breast cancer: Discordance of receptor status between primary and metastatic site. Anticancer Research. 2018 Oct 1;38(10):6023-6.

Tang YI, Liu Y, Zhao W, Yu T, Yu H. Caspase-8 polymorphisms and risk of oral squamous cell carcinoma. Experimental and Therapeutic Medicine. 2015 Dec 1;10(6):2267-76.

Li C, Wang L, Su J, Zhang R, Fu L, Zhou Y. mRNA expression and hypermethylation of tumor suppressor genes apoptosis protease activating factor-1 and death-associated protein kinase in oral squamous cell carcinoma. Oncology Letters. 2013 Jul 1;6(1):280-6.

Gordon M, Baksh S. RASSF1A: not a prototypical Ras effector. Small GTPases. 2011 May 1;2(3):5729-40.

Zhang Z, Wang L, Wei S, Liu Z, Wang LE, Sturgis EM, Wei Q. Polymorphisms of the DNA repair gene MGMT and risk and progression of head and neck cancer. DNA Repair. 2010 May 4;9(5): 558-66.

Lee S, Kim WH, Jung HY, Yang MH, Kang GH. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. The American Journal of Pathology. 2002 Sep 1;161(3): 1015-22.

Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, Ralhan R. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sciences. 2010 Jul 17;87(3-4):83-91.

Kang S, Dong SM, Park NH. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer. Gynecologic Oncology. 2010 Jul 1;118(1):58-63.

Issa JP. DNA methylation as a therapeutic target in cancer. Clinical Cancer Research. 2007 Mar 15;13(6):1634-7.

Majumder MM, Tamborero D, Anttila P, Silvennoinen R, Lievonen J, Eldfors S, Kumar A, Parsons A, Suvela M, Jantunen E, Porkka K. Increased mutational burden and alterations to DNA damage repair genes are associated with poor prognosis and sensitivity to PI3K-mTOR inhibitors in multiple myeloma. Clinical Lymphoma Myeloma and Leukemia. 2017 Feb 1;17(1):e2.

Welti J, Sharp A, Yuan W, Dolling D, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, Crespo M. Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC). Clinical Cancer Research. 2018 Jul 1;24(13):3149-62.

Tang X, et al. Epigenetic targeting of microRNAs in oral cancer stem cells: Emerging therapeutic approaches in cancer treatment. Int J Mol Sci. 2020;21(20):7710.

Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K, Takenoshita S. CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncology Reports. 2009 Oct 1;22(4):745-55.

Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): A potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncology. 2009 Jun;5(5): 601-12.

Vered M, Dayan D, Dobriyan A, Yahalom R, Shalmon B, Barshack I, Bedrin L, Talmi YP, Taicher S. Oral tongue squamous cell carcinoma: Recurrent disease is associated with histopathologic risk score and young age. Journal of Cancer Research and Clinical Oncology. 2010 Jul;136:1039-48.

Carmona FJ, Esteller M. Human cancer epigenetics. Environmental Epigenomics in Health and Disease: Epigenetics and Complex Diseases. 2013;269-93.

Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010 Jan 1;31(1):27-36.

Ushio R, Hiroi M, Matsumoto A, Mori K, Yamamoto N, Ohmori Y. Enhanced cytotoxic effects in human oral squamous cell carcinoma cells treated with combined methyltransferase inhibitors and histone deacetylase inhibitors. Biomedicines. 2022;10(4):763.